177 related articles for article (PubMed ID: 15593373)
1. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):393-401. PubMed ID: 15593373
[TBL] [Abstract][Full Text] [Related]
2. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):383-92. PubMed ID: 15599937
[TBL] [Abstract][Full Text] [Related]
3. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.
Delaney G; Jacob S; Barton M
Cancer; 2006 Jan; 106(2):453-65. PubMed ID: 16355366
[TBL] [Abstract][Full Text] [Related]
4. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies.
Delaney G; Jacob S; Barton M
Cancer; 2005 Feb; 103(3):462-73. PubMed ID: 15612081
[TBL] [Abstract][Full Text] [Related]
5. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Mar; 100(6):1293-301. PubMed ID: 15022299
[TBL] [Abstract][Full Text] [Related]
6. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):671-81. PubMed ID: 15305396
[TBL] [Abstract][Full Text] [Related]
7. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):682-92. PubMed ID: 15305397
[TBL] [Abstract][Full Text] [Related]
8. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.
Delaney G; Jacob S; Featherstone C; Barton M
Cancer; 2005 Sep; 104(6):1129-37. PubMed ID: 16080176
[TBL] [Abstract][Full Text] [Related]
9. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2003 Nov; 98(9):1977-86. PubMed ID: 14584082
[TBL] [Abstract][Full Text] [Related]
10. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Aug; 101(4):657-70. PubMed ID: 15305395
[TBL] [Abstract][Full Text] [Related]
11. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.
Delaney G; Jacob S; Barton M
Cancer; 2005 Jun; 103(11):2216-27. PubMed ID: 15856428
[TBL] [Abstract][Full Text] [Related]
12. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.
Delaney G; Shafiq J; Chappell G; Barton M
Cancer; 2008 May; 112(9):1912-22. PubMed ID: 18318431
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism in the hematologic malignancies.
Falanga A; Marchetti M
J Clin Oncol; 2009 Oct; 27(29):4848-57. PubMed ID: 19752334
[TBL] [Abstract][Full Text] [Related]
14. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma.
Wright JD; St Clair CM; Deutsch I; Burke WM; Gorrochurn P; Sun X; Herzog TJ
Cancer; 2010 May; 116(10):2486-92. PubMed ID: 20209618
[TBL] [Abstract][Full Text] [Related]
15. Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients.
Jacob S; Wong K; Delaney GP; Adams P; Barton MB
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):56-64. PubMed ID: 19969443
[TBL] [Abstract][Full Text] [Related]
16. An experience with sixty cases of haematological malignancies; a clinico haematological correlation.
Idris M; Shah SH; Fareed J; Gul N
J Ayub Med Coll Abbottabad; 2004; 16(4):51-4. PubMed ID: 15762065
[TBL] [Abstract][Full Text] [Related]
17. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis.
Sari I; Altuntas F; Hacioglu S; Kocyigit I; Sevinc A; Sacar S; Deniz K; Alp E; Eser B; Yildiz O; Kaynar L; Unal A; Cetin M
Am J Hematol; 2008 Apr; 83(4):334-9. PubMed ID: 18069671
[TBL] [Abstract][Full Text] [Related]
18. [Survival outcomes of T-cell non-Hodgkin's lymphoma: a report of 111 cases].
Huang Y; Lin TY; Wu QL; Su ZL; Huang HQ; Xia ZJ; Sun XF; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Apr; 24(4):470-4. PubMed ID: 15820072
[TBL] [Abstract][Full Text] [Related]
19. Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.
Alexander BM; Wechsler D; Braun TM; Levine J; Herman J; Yanik G; Hutchinson R; Pierce LJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1191-6. PubMed ID: 15978741
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
